<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=1200, user-scalable=yes, initial-scale=0.4, minimum-scale=0.1">
    <title>Xylazine - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <link rel="icon" type="image/svg+xml" href="/Dyo-s-Dubious-Domain/assets/logo.svg">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
        
        // Force desktop behavior by overriding mobile detection
        window.isMobile = false;
        window.isDesktop = true;
        
        // Override any mobile detection functions
        if (window.matchMedia) {
            const originalMatchMedia = window.matchMedia;
            window.matchMedia = function(query) {
                // Force desktop media queries to always match for min-width
                // and mobile queries to never match
                if (query.includes('max-width') && (query.includes('768px') || query.includes('480px'))) {
                    return { matches: false, addListener: function() {}, removeListener: function() {} };
                }
                if (query.includes('min-width')) {
                    return { matches: true, addListener: function() {}, removeListener: function() {} };
                }
                return originalMatchMedia.call(this, query);
            };
        }
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚ÜÅE<a href="/dyos-domain/depressants/">Depressants</a> ‚ÜÅE<span>Xylazine</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üßÅEXylazine</h1>
        <h2 class="chemical-name">N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine</h2>
        
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Xylazine" 
                data-category="Depressants" 
                data-chemical="N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <span class="alt-name veterinary">Xyla</span>
            <span class="alt-name street">Zombie Drug</span>
            <span class="alt-name street">Tranq</span>
            <span class="alt-name street">Zombie Dope</span>
            <span class="alt-name veterinary">Rompun</span>
            <span class="alt-name veterinary">Anased</span>
            <span class="alt-name street">Tranq Dope</span>
            <span class="alt-name street">Flesh-Eating Drug</span>
            <span class="alt-name chemical">Alpha-2 Agonist</span>
            <span class="alt-name street">Sleep Cut</span>
            <span class="alt-name street">Skin Rot</span>
            <span class="alt-name veterinary">Sedazine</span>
            <span class="alt-name street">Philadelphia Zombie</span>
            <span class="alt-name medical">Non-Opioid Sedative</span>
            <span class="alt-name street">Necrosis Drug</span>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category depressant">Depressant</span>
          <span class="legal-status veterinary">Veterinary Use</span>
          <span class="duration long">4-8 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/Dyo-s-Dubious-Domain/assets/substances/xylazine.jpg" alt="Xylazine vial and skin lesions" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>Thiazine structure - veterinary alpha-2 adrenergic agonist</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Veterinary Form</h4>
          <ul>
            <li><strong>Pharmaceutical:</strong> Clear sterile solution in vials</li>
            <li><strong>Concentration:</strong> 20mg/ml, 100mg/ml (veterinary)</li>
            <li><strong>Appearance:</strong> Colorless to pale yellow liquid</li>
            <li><strong>Packaging:</strong> Medical vials with proper labeling</li>
            <li><strong>Odor:</strong> Chemical/medicinal smell</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Street Contamination</h4>
          <ul>
            <li><strong>Mixed powders:</strong> White/off-white powder mixed with fentanyl</li>
            <li><strong>Pressed pills:</strong> Counterfeit pills containing xylazine</li>
            <li><strong>Liquid preparations:</strong> Injectable solutions with unknown concentration</li>
            <li><strong>Heroin adulteration:</strong> Mixed into street heroin supplies</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†ÔøΩEÔøΩECritical Contamination Risks</h4>
          <p><strong>Fentanyl contamination:</strong> Nearly all street xylazine contains deadly fentanyl</p>
          <p><strong>Unknown concentrations:</strong> Street dosing completely unpredictable</p>
          <p><strong>Veterinary theft:</strong> Diverted from legitimate veterinary supplies</p>
          <p><strong>Impurities:</strong> Manufacturing byproducts and contaminants</p>
          <p><strong>Cross-contamination:</strong> Mixed with other dangerous adulterants</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Information</h3>
      <div class="dosage-warning">
        <h4>‚ö†ÔøΩEÔøΩENO HUMAN DOSAGE DATA</h4>
        <p><strong>VETERINARY ONLY.</strong> Xylazine is designed for animals and has no established human dosage. Street use leads to unpredictable sedation, respiratory depression, and horrific skin necrosis. <strong>This substance should NEVER be used by humans.</strong></p>
      </div>
      
      <div class="dosage-chart">
        <div class="dosage-disclaimer">
          <h4>‚ö†ÔøΩEÔøΩEVETERINARY DOSING REFERENCE ONLY</h4>
          <p><strong>The following is veterinary dosing information provided solely for educational purposes. Human use is extremely dangerous and causes skin necrosis.</strong></p>
        </div>
        
        <div class="dose-range threshold">
          <span class="range-label">Veterinary (Large Animals)</span>
          <span class="dose-amount">0.1-0.3 mg/kg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Veterinary (Small Animals)</span>
          <span class="dose-amount">0.5-2.2 mg/kg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Human Contamination</span>
          <span class="dose-amount">Unknown - Causes Necrosis</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Street Mixtures</span>
          <span class="dose-amount">Unpredictable - Flesh Damage</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Any Human Use</span>
          <span class="dose-amount">Guaranteed Tissue Death</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Critical Risk Factors</h4>
        <ul>
          <li><strong>No human safety data:</strong> Designed for veterinary use only</li>
          <li><strong>Immediate skin necrosis:</strong> Begins within hours of first exposure</li>
          <li><strong>Naloxone resistant:</strong> Cannot be reversed with standard overdose antidotes</li>
          <li><strong>Spreads beyond injection sites:</strong> Necrosis occurs even without direct injection</li>
          <li><strong>Progressive tissue death:</strong> Continues even after stopping use</li>
          <li><strong>Amputation risk:</strong> Advanced necrosis requires limb amputation</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>LIFE-SAVING WARNING:</strong> Any human exposure to xylazine risks permanent tissue damage and horrific skin necrosis. Seek immediate medical attention for any suspected exposure.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Human Contamination)</h4>
        <div class="timeline-item">
          <span class="time">T+0:15-0:30</span>
          <span class="effect">Onset - sedation, respiratory depression, skin damage begins</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+0:30-4:00</span>
          <span class="effect">Peak - deep sedation, unconsciousness, tissue necrosis visible</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Duration - continued sedation, progressive skin death</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00+</span>
          <span class="effect">Recovery - sedation fades, skin necrosis permanent and progressive</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÅEIntended Veterinary Effects</h4>
          <ul>
            <li>Muscle relaxation in animals</li>
            <li>Sedation for veterinary procedures</li>
            <li>Analgesia (pain relief) in animals</li>
            <li>Reduced anxiety in veterinary settings</li>
            <li>Controlled anesthesia induction</li>
            <li>Reversible with specific antidotes (animals)</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùÅEHuman Toxicity Effects</h4>
          <ul>
            <li>Horrific skin necrosis and tissue death</li>
            <li>Severe respiratory depression</li>
            <li>Dangerous hypotension (low blood pressure)</li>
            <li>Bradycardia (dangerously slow heart rate)</li>
            <li>Deep unconsciousness and coma</li>
            <li>Naloxone-resistant overdose</li>
            <li>Progressive flesh-eating lesions</li>
            <li>Gangrene and infection</li>
            <li>Amputation requirements</li>
            <li>Permanent disfigurement</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Xylazine is a selective Œ±‚ÇÅEadrenergic receptor agonist that produces sedation, muscle relaxation, and analgesia through central nervous system depression. Unlike opioids, it acts on adrenergic pathways, making it unresponsive to naloxone. Its vasoconstrictive properties cause severe tissue ischemia and necrosis in humans.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor">Œ±‚ÇÅEAdrenergic Receptors</span>
            <span class="activity">High affinity agonist</span>
            <span class="effect">Sedation, analgesia, hypotension</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">Œ±‚ÇÅEAdrenergic Receptors</span>
            <span class="activity">Partial agonist</span>
            <span class="effect">Vasoconstriction, tissue ischemia</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">Imidazoline Receptors</span>
            <span class="activity">Moderate affinity</span>
            <span class="effect">Additional cardiovascular effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">GABA Receptors</span>
            <span class="activity">Indirect modulation</span>
            <span class="effect">Enhanced sedation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor">Opioid Receptors</span>
            <span class="activity">No activity</span>
            <span class="effect">Naloxone resistance</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary metabolism:</strong> Hepatic via CYP450 enzymes</p>
          <p><strong>Half-life:</strong> 1.3-2.9 hours in animals (human data limited)</p>
          <p><strong>Bioavailability:</strong> High via injection, lower oral</p>
          <p><strong>Peak effects:</strong> 10-30 minutes after injection</p>
          <p><strong>Elimination:</strong> 95% renal excretion, 5% unchanged</p>
          <p><strong>Species variation:</strong> Metabolism differs significantly between species</p>
        </div>

        <h4>Tissue Damage Mechanisms</h4>
        <div class="neurotoxicity-info">
          <p><strong>Vasoconstriction:</strong> Severe reduction in blood flow causes tissue ischemia</p>
          <p><strong>Direct cytotoxicity:</strong> Chemical damage to skin and subcutaneous tissue</p>
          <p><strong>Inflammatory response:</strong> Triggers immune-mediated tissue destruction</p>
          <p><strong>Hypoxic injury:</strong> Reduced oxygen delivery causes cell death</p>
          <p><strong>Progressive necrosis:</strong> Damage spreads beyond initial contact area</p>
          <p><strong>Impaired healing:</strong> Continued exposure prevents tissue repair</p>
        </div>

        <h4>Unique Pharmacological Dangers</h4>
        <ul>
          <li><strong>Naloxone resistance:</strong> Standard opioid antidote completely ineffective</li>
          <li><strong>Tissue necrosis:</strong> Causes flesh death at any exposure level</li>
          <li><strong>Species mismatch:</strong> Designed for animals, not humans</li>
          <li><strong>Cardiovascular toxicity:</strong> Dangerous effects on heart and blood vessels</li>
          <li><strong>Delayed recognition:</strong> Sedation masks early tissue damage</li>
          <li><strong>Progressive damage:</strong> Necrosis continues after drug clearance</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†ÔøΩEÔøΩESafety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® ABSOLUTE CRITICAL WARNINGS</h4>
          <ul>
            <li><strong>NO HUMAN USE:</strong> Veterinary drug only - never for human consumption</li>
            <li><strong>Guaranteed skin necrosis:</strong> Any exposure causes permanent tissue damage</li>
            <li><strong>Naloxone ineffective:</strong> Standard overdose reversal will not work</li>
            <li><strong>Progressive damage:</strong> Tissue death continues after stopping use</li>
            <li><strong>Amputation risk:</strong> Advanced necrosis requires surgical removal</li>
            <li><strong>Spreads beyond injection sites:</strong> Affects areas never injected</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°ÔøΩEÔøΩEEmergency Response Only</h4>
          <ul>
            <li><strong>Immediate medical attention:</strong> Any suspected exposure requires emergency care</li>
            <li><strong>Wound care specialist:</strong> Dermatology/plastic surgery consultation needed</li>
            <li><strong>Alpha-2 antagonists:</strong> Atipamezole may reverse some effects (not skin damage)</li>
            <li><strong>Supportive care:</strong> Blood pressure and respiratory support</li>
            <li><strong>Infection prevention:</strong> Antibiotics for necrotic tissue</li>
            <li><strong>Surgical debridement:</strong> Dead tissue removal required</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Universal Contraindications</h4>
        <p><strong>No human use under any circumstances:</strong> Xylazine is exclusively for veterinary use. Any human exposure risks permanent disfigurement and tissue death. There are no exceptions to this warning.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏ÅEDrug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Lethal Combinations</h4>
          <ul>
            <li><strong>Opioids (any):</strong> Synergistic respiratory depression, naloxone ineffective</li>
            <li><strong>Alcohol:</strong> Dangerous CNS depression plus tissue necrosis</li>
            <li><strong>Benzodiazepines:</strong> Fatal sedation and respiratory failure</li>
            <li><strong>Other alpha-2 agonists:</strong> Extreme hypotension and bradycardia</li>
            <li><strong>CNS depressants:</strong> Combined sedation causes respiratory arrest</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Dangerous Interactions</h4>
          <ul>
            <li><strong>Beta-blockers:</strong> Severe cardiovascular depression</li>
            <li><strong>Calcium channel blockers:</strong> Extreme hypotension</li>
            <li><strong>Antihypertensives:</strong> Dangerous blood pressure drops</li>
            <li><strong>Muscle relaxants:</strong> Enhanced sedation and respiratory depression</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† All Substances Dangerous</h4>
          <ul>
            <li><strong>No safe combinations:</strong> Xylazine makes all drug interactions more dangerous</li>
            <li><strong>Medical procedures:</strong> Anesthesia complications due to alpha-2 effects</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏ÅELegal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United States</h4>
            <p>Veterinary prescription drug - human use illegal and extremely dangerous</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United Kingdom</h4>
            <p>Prescription-only medicine (POM-V) - veterinary use only</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE European Union</h4>
            <p>Controlled veterinary substance across member states</p>
          </div>
          <div class="jurisdiction">
            <h4>üåç International</h4>
            <p>WHO and global health agencies monitor for diversion</p>
          </div>
        </div>
        
        <div class="therapeutic-status">
          <h4>üè• Medical Status</h4>
          <p>Xylazine is approved exclusively for veterinary sedation and anesthesia. It has no approved human medical uses and poses extreme risks including tissue necrosis, naloxone-resistant overdose, and permanent disfigurement.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1962</span>
          <p>First synthesized by Bayer for veterinary anesthesia</p>
        </div>
        <div class="history-event">
          <span class="year">1970s</span>
          <p>Becomes standard veterinary sedative worldwide</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>First reports of diversion to illicit drug markets</p>
        </div>
        <div class="history-event">
          <span class="year">2015</span>
          <p>Emerges in Philadelphia street drug supply</p>
        </div>
        <div class="history-event">
          <span class="year">2019</span>
          <p>Widespread contamination of US fentanyl supply</p>
        </div>
        <div class="history-event">
          <span class="year">2022</span>
          <p>Found in 90%+ of street fentanyl samples in some areas</p>
        </div>
        <div class="history-event">
          <span class="year">2023</span>
          <p>Major public health emergency declared due to "zombie drug" epidemic</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Cultural Impact</h4>
        <p>Xylazine represents a new phase in the overdose crisis - a adulterant that causes horrific visible injuries while being resistant to standard overdose reversal. Its emergence has transformed harm reduction approaches and highlighted the devastating consequences of a contaminated drug supply.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Treatment of Necrotic Wounds</h4>
          <p>Research into optimal wound care protocols for xylazine-induced skin necrosis, including surgical techniques and wound healing approaches.</p>
        </div>
        
        <div class="research-item">
          <h4>Overdose Reversal Strategies</h4>
          <p>Investigation into treatment protocols for xylazine-contaminated overdoses, including combination therapies and supportive care measures.</p>
        </div>
        
        <div class="research-item">
          <h4>Detection Methods</h4>
          <p>Development of rapid testing to identify xylazine contamination in drug supplies and inform harm reduction interventions.</p>
        </div>
        
        <div class="research-item">
          <h4>Prevention Strategies</h4>
          <p>Public health research into effective education and intervention strategies to prevent xylazine exposure and its devastating consequences.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Emergency Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Emergency Services</h4>
        <ul>
          <li><strong>Emergency:</strong> Call 911/999/112 immediately</li>
          <li><strong>Poison Control:</strong> 1-800-222-1222</li>
          <li><strong>Wound care:</strong> Immediate medical evaluation required</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><strong>Alpha-2 antagonist:</strong> Atipamezole may help (veterinary antidote)</li>
          <li><strong>Wound specialist:</strong> Dermatology/plastic surgery consultation</li>
          <li><strong>Infection control:</strong> Immediate antibiotic evaluation</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support Resources</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/">SAMHSA</a> - Treatment locator</li>
          <li><strong>Harm reduction:</strong> Needle exchanges and wound care</li>
          <li><strong>Surgical support:</strong> Plastic surgery for wound management</li>
        </ul>
      </div>
    </div>
  </div>

</div>


    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/Dyo-s-Dubious-Domain/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>